Eytan M. Stein

16.1k total citations
203 papers, 3.4k citations indexed

About

Eytan M. Stein is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Eytan M. Stein has authored 203 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Hematology, 94 papers in Molecular Biology and 57 papers in Genetics. Recurrent topics in Eytan M. Stein's work include Acute Myeloid Leukemia Research (157 papers), Chronic Myeloid Leukemia Treatments (40 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (39 papers). Eytan M. Stein is often cited by papers focused on Acute Myeloid Leukemia Research (157 papers), Chronic Myeloid Leukemia Treatments (40 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (39 papers). Eytan M. Stein collaborates with scholars based in United States, France and Germany. Eytan M. Stein's co-authors include Martin S. Tallman, Courtney D. DiNardo, Stéphane de Botton, Amir T. Fathi, Hagop M. Kantarjian, Anthony S. Stein, Eyal C. Attar, Jessica K. Altman, Daniel J. DeAngelo and Ross L. Levine and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Eytan M. Stein

192 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eytan M. Stein United States 28 2.3k 2.0k 636 617 511 203 3.4k
Jan Braess Germany 27 1.8k 0.8× 1.1k 0.6× 540 0.8× 409 0.7× 491 1.0× 98 2.4k
Olatoyosi Odenike United States 33 2.2k 0.9× 1.6k 0.8× 1.1k 1.7× 723 1.2× 565 1.1× 156 3.6k
Agnieszka Wierzbowska Poland 22 1.5k 0.6× 1.1k 0.6× 461 0.7× 483 0.8× 435 0.9× 108 2.3k
Keith W. Pratz United States 33 4.2k 1.8× 2.5k 1.3× 1.4k 2.1× 962 1.6× 917 1.8× 128 5.2k
Deborah Berg United States 24 2.9k 1.3× 2.0k 1.0× 584 0.9× 1.1k 1.9× 819 1.6× 66 3.6k
Lars Möllgård Sweden 20 1.5k 0.6× 922 0.5× 627 1.0× 531 0.9× 516 1.0× 41 2.2k
Thomas Pabst Switzerland 30 2.5k 1.1× 1.6k 0.8× 713 1.1× 1.2k 1.9× 656 1.3× 180 4.3k
Yesid Alvarado United States 26 1.6k 0.7× 777 0.4× 816 1.3× 573 0.9× 533 1.0× 153 2.4k
Ramón V. Tiu United States 40 3.5k 1.5× 2.2k 1.1× 2.0k 3.1× 550 0.9× 429 0.8× 159 5.0k
Mario Tiribelli Italy 25 1.3k 0.5× 656 0.3× 922 1.4× 610 1.0× 277 0.5× 97 2.2k

Countries citing papers authored by Eytan M. Stein

Since Specialization
Citations

This map shows the geographic impact of Eytan M. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eytan M. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eytan M. Stein more than expected).

Fields of papers citing papers by Eytan M. Stein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eytan M. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eytan M. Stein. The network helps show where Eytan M. Stein may publish in the future.

Co-authorship network of co-authors of Eytan M. Stein

This figure shows the co-authorship network connecting the top 25 collaborators of Eytan M. Stein. A scholar is included among the top collaborators of Eytan M. Stein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eytan M. Stein. Eytan M. Stein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lachowiez, Curtis A., Andrew J. Belli, Laura L. Fernandes, et al.. (2025). Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy. JCO Oncology Practice. 22(1). 66–73. 1 indexed citations
2.
Terry, Alexander R., Andriy Derkach, Kuo‐Kai Chin, et al.. (2025). Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction. Blood Advances. 9(13). 3213–3222.
3.
Issa, Ghayas C., Sheng F. Cai, Álex Bataller, Hagop M. Kantarjian, & Eytan M. Stein. (2025). Combination Strategies with Menin Inhibitors for Acute Leukemia. Blood Cancer Discovery. 6(6). 547–560. 1 indexed citations
4.
Chin, Kuo‐Kai, Brian Ball, Yasmin Abaza, et al.. (2025). Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure. Blood Advances. 10(5). 1537–1547.
5.
Biswas, Jeetayu, et al.. (2024). Aberrant pre-mRNA processing in cancer. The Journal of Experimental Medicine. 221(11). 1 indexed citations
6.
7.
Montesinos, Pau, Amir T. Fathi, Stéphane de Botton, et al.. (2024). Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood Advances. 8(10). 2509–2519. 7 indexed citations
8.
Chin, Kuo‐Kai, Yannis K. Valtis, Andriy Derkach, et al.. (2024). Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia. PubMed. 1(4). 100038–100038. 3 indexed citations
9.
Kantarjian, Hagop M., Courtney D. DiNardo, Tapan M. Kadia, et al.. (2024). Acute myeloid leukemia management and research in 2025. CA A Cancer Journal for Clinicians. 75(1). 46–67. 35 indexed citations
10.
DiNardo, Courtney D., Stéphane de Botton, Daniel A. Pollyea, et al.. (2023). Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study. American Journal of Hematology. 98(9). E233–E236. 5 indexed citations
11.
Bewersdorf, Jan Philipp, Maximilian Stahl, Justin Taylor, et al.. (2023). E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia. 37(12). 2512–2516. 36 indexed citations
12.
Epstein‐Peterson, Zachary D., Andriy Derkach, Susan M. Geyer, et al.. (2022). Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Advances. 6(11). 3433–3439. 7 indexed citations
13.
Stahl, Maximilian, Kamal Menghrajani, Andriy Derkach, et al.. (2021). Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances. 5(5). 1552–1564. 108 indexed citations
14.
Choe, Sung, Hongfang Wang, Courtney D. DiNardo, et al.. (2019). Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia. Blood. 134(Supplement_1). 545–545. 4 indexed citations
15.
Menghrajani, Kamal, Sheng F. Cai, Sean M. Devlin, et al.. (2019). A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia. Blood. 134(Supplement_1). 2655–2655. 12 indexed citations
16.
Rampal, Raajit K., Srđan Verstovšek, Sean M. Devlin, et al.. (2019). Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. Blood. 134(Supplement_1). 4163–4163. 26 indexed citations
17.
Shih, Alan H., Cem Meydan, Kaitlyn Shank, et al.. (2017). Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2 - and TET2 -Mutant Acute Myeloid Leukemia. Cancer Discovery. 7(5). 494–505. 71 indexed citations
18.
Amatangelo, Michael, Lynn Quek, Alan H. Shih, et al.. (2017). Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 130(6). 732–741. 249 indexed citations
19.
Goldberg, Aaron D., Troy Z. Horvat, Meier Hsu, et al.. (2017). Venetoclax Combined with Either a Hypomethylating Agent or Low-Dose Cytarabine Shows Activity in Relapsed and Refractory Myeloid Malignancies. Blood. 130. 1353–1353. 18 indexed citations
20.
Stone, Richard M., Sung Choe, Vickie Zhang, et al.. (2017). Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML. Blood. 130. 2684–2684. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jan Braess Breakdown of academic impact, for papers by Olatoyosi Odenike Breakdown of academic impact, for papers by Agnieszka Wierzbowska Breakdown of academic impact, for papers by Keith W. Pratz Breakdown of academic impact, for papers by Deborah Berg Breakdown of academic impact, for papers by Lars Möllgård Breakdown of academic impact, for papers by Thomas Pabst Breakdown of academic impact, for papers by Yesid Alvarado Breakdown of academic impact, for papers by Ramón V. Tiu Breakdown of academic impact, for papers by Mario Tiribelli
Rankless by CCL
2026